Lazard Asset Management
CTKB icon

Lazard Asset Management’s Cytek Biosciences CTKB Stock Holding History

Lazard Asset Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,972
Closed -$75K – 2332
2025
Q1 		$75K Buy
18,972
+2
+0% +$10 ﹤0.01% 1893
2024
Q4 		$122K Buy
+18,970
New +$113K ﹤0.01% 1743
2023
Q1 		– Sell
-1,175
Closed -$11K – 2339
2022
Q4 		$11K Sell
1,175
-1,130
-49% -$15.2K ﹤0.01% 2187
2022
Q3 		$33K Sell
2,305
-4,250
-65% -$55.2K ﹤0.01% 1952
2022
Q2 		$70K Buy
+6,555
New +$65.2K ﹤0.01% 1662

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Lazard Asset Management's CTKB Position: Q2 2025 in Review

Lazard Asset Management sold out of Cytek Biosciences (CTKB) in Q2 2025, closing a stake of 18,972 shares — an estimated $75K sold.

Lazard Asset Management first reported a position in CTKB in Q2 2022 and held it in 5 quarters. The position peaked at $122K in Q4 2024. 158 funds tracked by Wall St. Rank hold CTKB as of Q2 2025.

  • Lazard Asset Management reported no remaining Cytek Biosciences position as of Q2 2025 after selling out during the quarter.
  • Lazard Asset Management sold 18,972 Cytek Biosciences shares in Q2 2025, an estimated $75K.
  • Lazard Asset Management first reported a position in Cytek Biosciences in Q2 2022 and held it in 5 quarters.
  • Lazard Asset Management's Cytek Biosciences position peaked at $122K in Q4 2024.
  • 158 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2025.

Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.